JP2016522266A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016522266A5 JP2016522266A5 JP2016521862A JP2016521862A JP2016522266A5 JP 2016522266 A5 JP2016522266 A5 JP 2016522266A5 JP 2016521862 A JP2016521862 A JP 2016521862A JP 2016521862 A JP2016521862 A JP 2016521862A JP 2016522266 A5 JP2016522266 A5 JP 2016522266A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- pharmaceutical composition
- acceptable salt
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000006413 ring segment Chemical group 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 239000011593 sulfur Substances 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 101100004408 Arabidopsis thaliana BIG gene Proteins 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 101100485279 Drosophila melanogaster emb gene Proteins 0.000 claims 1
- 102100029095 Exportin-1 Human genes 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 101100485284 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CRM1 gene Proteins 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 101150094313 XPO1 gene Proteins 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 108700002148 exportin 1 Proteins 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 235000012631 food intake Nutrition 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 208000037824 growth disorder Diseases 0.000 claims 1
- 210000002768 hair cell Anatomy 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- -1 oxadiazolyl compound Chemical class 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 230000008467 tissue growth Effects 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361838172P | 2013-06-21 | 2013-06-21 | |
| US61/838,172 | 2013-06-21 | ||
| PCT/US2014/043479 WO2014205389A1 (en) | 2013-06-21 | 2014-06-20 | Nuclear transport modulators and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020115772A Division JP7061161B2 (ja) | 2013-06-21 | 2020-07-03 | 核内輸送調節因子およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016522266A JP2016522266A (ja) | 2016-07-28 |
| JP2016522266A5 true JP2016522266A5 (cg-RX-API-DMAC10.html) | 2017-07-27 |
| JP6730922B2 JP6730922B2 (ja) | 2020-07-29 |
Family
ID=51177201
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016521862A Active JP6730922B2 (ja) | 2013-06-21 | 2014-06-20 | 核内輸送調節因子およびその使用 |
| JP2020115772A Active JP7061161B2 (ja) | 2013-06-21 | 2020-07-03 | 核内輸送調節因子およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020115772A Active JP7061161B2 (ja) | 2013-06-21 | 2020-07-03 | 核内輸送調節因子およびその使用 |
Country Status (28)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103002742B (zh) | 2010-03-05 | 2016-07-13 | 卡尔约药物治疗公司 | 核转运调节剂及其应用 |
| CA2824808A1 (en) | 2011-01-17 | 2012-07-26 | Karyopharm Therapeutics, Inc. | Olefin containing nuclear transport modulators and uses thereof |
| JP6006794B2 (ja) | 2011-07-29 | 2016-10-12 | カリオファーム セラピューティクス，インコーポレイテッド | 核内輸送調節因子およびその使用 |
| KR20200088518A (ko) | 2011-07-29 | 2020-07-22 | 카리오팜 쎄라퓨틱스, 인코포레이티드 | 하이드라지드 함유 핵 수송 조절인자 및 이의 용도 |
| HUE040427T2 (hu) | 2012-05-09 | 2019-03-28 | Biogen Ma Inc | Nukleáris transzportmodulátorok és felhasználásuk |
| EP2968278B8 (en) | 2013-03-15 | 2019-05-22 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using crm1 inhibitors |
| MX365939B (es) | 2013-06-21 | 2019-06-19 | Karyopharm Therapeutics Inc | Moduladores del transporte nuclear y usos de los mismos. |
| SG11201700789SA (en) | 2014-08-15 | 2017-02-27 | Karyopharm Therapeutics Inc | Polymorphs of selinexor |
| US10709706B2 (en) * | 2015-12-31 | 2020-07-14 | Karopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| US10526295B2 (en) | 2015-12-31 | 2020-01-07 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| US11065230B2 (en) * | 2016-09-16 | 2021-07-20 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of systemic mastocytosis |
| US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
| EP3737665B1 (en) | 2018-01-10 | 2026-01-07 | XWPharma Ltd. | Prodrugs of ketamine, compositions and uses thereof |
| WO2019232724A1 (en) | 2018-06-06 | 2019-12-12 | Xw Laboratories, Inc. | Compounds as nuclear transport modulators and uses thereof |
| WO2020051294A1 (en) * | 2018-09-07 | 2020-03-12 | Karyopharm Therapeutics Inc. | The combination of xpo1 inhibitors and second agents for the treatment of prostate cancer |
| WO2020092965A1 (en) * | 2018-11-01 | 2020-05-07 | Karyopharm Therapeutics Inc. | E2f1 as a biomarker for treatments using xpo1 inhibitors |
| MX2021006527A (es) | 2018-12-05 | 2021-07-21 | Scohia Pharma Inc | Compuesto macrociclico y su uso. |
| CN111606890A (zh) * | 2019-02-26 | 2020-09-01 | 微境生物医药科技(上海)有限公司 | 含丙烯酰基的核转运调节剂及其用途 |
| MA55808A (fr) | 2019-05-01 | 2022-03-09 | Karyopharm Therapeutics Inc | Procédé de préparation d'inhibiteurs de xpo1 et intermédiaires destinés à être utilisés dans la préparation d'inhibiteurs de xpo1 |
| WO2021202745A1 (en) | 2020-03-31 | 2021-10-07 | Karyopharm Therapeutics Inc. | Treatment of covid-19 with a sine compound |
| CN113880803B (zh) * | 2020-07-03 | 2024-07-02 | 上海天慈国际药业有限公司 | 一种xpo-1抑制剂的制备方法 |
| WO2022089629A1 (zh) * | 2020-11-02 | 2022-05-05 | 江苏柯菲平医药股份有限公司 | 1,2,4-三氮唑衍生物及其制备方法和用途 |
| CN112294819B (zh) * | 2020-12-03 | 2021-12-14 | 中国人民解放军军事科学院军事医学研究院 | 一种炎症小体抑制剂及其应用 |
| CN113045550A (zh) * | 2021-03-12 | 2021-06-29 | 深圳济康医药科技有限公司 | 一种三氮唑类衍生物及其制备方法和应用 |
| US20240287041A1 (en) * | 2021-05-20 | 2024-08-29 | Karyopharm Therapeutics Inc. | Methods of synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms |
| CN113248474A (zh) * | 2021-05-24 | 2021-08-13 | 王能能 | 五元氮唑杂环衍生物及其制备方法和用途 |
| EP4559522A3 (en) | 2021-08-13 | 2025-07-16 | XWPharma Ltd. | Pharmaceutical compositions and oral dosage forms of ketamine derivatives |
| CN117940409A (zh) * | 2021-09-08 | 2024-04-26 | 南京明德新药研发有限公司 | 丙烯酰胺类化合物及其应用 |
| JP2024539922A (ja) * | 2021-10-29 | 2024-10-31 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | ピリジル含有化合物 |
| CN119053594A (zh) * | 2022-01-12 | 2024-11-29 | 上海海雁医药科技有限公司 | 核转运调节剂及其用途 |
| WO2024102477A1 (en) | 2022-11-11 | 2024-05-16 | Karyopharm Therapeutics Inc. | Crystalline forms of eltanexor and process for preparing same |
| TWI863768B (zh) * | 2023-12-21 | 2024-11-21 | 友達光電股份有限公司 | 顯示裝置 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CS229934B2 (en) | 1981-07-07 | 1984-07-16 | Pfizer | Production method subst.indolylacryte acid derivative |
| KR840000529A (ko) | 1981-07-07 | 1984-02-25 | 콘스탄틴 루이스 클레멘트 | 인돌 유도체의 제조방법 |
| US4778796A (en) | 1985-07-19 | 1988-10-18 | Dainippon Pharmaceutical Co., Ltd. | ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same |
| IL97249A (en) | 1990-02-23 | 1995-01-24 | Takeda Chemical Industries Ltd | Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or |
| JP3111321B2 (ja) | 1990-02-23 | 2000-11-20 | 武田薬品工業株式会社 | 縮合チアゾール化合物 |
| US5541213A (en) | 1993-06-24 | 1996-07-30 | Eisai Co., Ltd. | Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility |
| US5468353A (en) | 1994-05-05 | 1995-11-21 | Minnesota Mining And Manufacturing Company | Mist suppressant for solvent extraction metal electrowinning |
| CN1088062C (zh) | 1994-11-23 | 2002-07-24 | 纽罗根公司 | 某些4－氨基甲基－2－取代的咪唑衍生物2－氨基甲基－4－取代的咪唑衍生物新的一族多巴胺受体亚型特异性配体 |
| US20030018025A1 (en) | 1995-06-07 | 2003-01-23 | Neurogen Corporation, Corporation Of The State Of Delaware | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands |
| JPH11513382A (ja) | 1995-10-20 | 1999-11-16 | ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法 |
| CN1088711C (zh) | 1996-04-04 | 2002-08-07 | 盐野义制药株式会社 | 头孢烯化合物及含该化合物的医药 |
| JP4054992B2 (ja) | 1996-04-25 | 2008-03-05 | 日産化学工業株式会社 | エチレン誘導体および有害生物防除剤 |
| IL126728A (en) | 1996-04-25 | 2009-12-24 | Nissan Chemical Ind Ltd | Ethylene derivatives and agrochemical compositions containing said derivatives as an active ingredient |
| DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| US5994398A (en) | 1996-12-11 | 1999-11-30 | Elan Pharmaceuticals, Inc. | Arylsulfonamides as phospholipase A2 inhibitors |
| JP4416198B2 (ja) | 1997-12-19 | 2010-02-17 | 武田薬品工業株式会社 | アニリド誘導体、その製造法および用途 |
| AU2960599A (en) | 1998-03-30 | 1999-10-18 | Akira Karasawa | Quinazoline derivatives |
| CO5271680A1 (es) | 2000-02-21 | 2003-04-30 | Smithkline Beecham Corp | Compuestos |
| ATE430567T1 (de) | 2000-09-29 | 2009-05-15 | Topotarget Uk Ltd | Carbaminsäurederivate enthaltend eine amidgruppe zur behandlung von malaria |
| AU2002327627B2 (en) | 2001-09-14 | 2006-09-14 | Methylgene Inc. | Inhibitors of histone deacetylase |
| WO2004037248A2 (en) | 2002-10-24 | 2004-05-06 | Carex Sa | Modulation of peroxisome proliferator activated receptors activity |
| DE10250743A1 (de) | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| AR041867A1 (es) | 2002-11-01 | 2005-06-01 | Takeda Pharmaceutical | Agente para prevenir o tratar neuropatia |
| JP4145230B2 (ja) | 2002-11-01 | 2008-09-03 | 武田薬品工業株式会社 | 神経障害の予防・治療剤 |
| US7342115B2 (en) | 2002-11-08 | 2008-03-11 | Neurogen Corporation | 3-substituted-6-aryl pyridines |
| EP1599447A1 (en) | 2003-02-28 | 2005-11-30 | Galderma Research & Development, S.N.C. | Ligands that modulate lxr-type receptors |
| MY149038A (en) | 2004-05-26 | 2013-07-15 | Eisai R&D Man Co Ltd | Cinnamide compound |
| KR20070050475A (ko) | 2004-08-11 | 2007-05-15 | 교린 세이야꾸 가부시키 가이샤 | 신규 환상 아미노 안식향산 유도체 |
| WO2006019020A1 (ja) | 2004-08-16 | 2006-02-23 | Sankyo Company, Limited | 置換されたウレア化合物 |
| JPWO2006088246A1 (ja) | 2005-02-18 | 2008-07-10 | 武田薬品工業株式会社 | Ｇｐｒ３４受容体機能調節剤 |
| BRPI0618589B8 (pt) | 2005-11-15 | 2021-05-25 | Otsuka Pharma Co Ltd | composto de oxazol, composição farmacêutica compreendendo o referido composto, processos de fabricação e usos dos mesmos |
| JP2007210929A (ja) | 2006-02-09 | 2007-08-23 | Sankyo Co Ltd | ウレア化合物を含有する医薬 |
| KR101464651B1 (ko) | 2006-03-09 | 2014-11-24 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 다환식 신나미드 유도체 |
| ES2452820T3 (es) | 2006-04-07 | 2014-04-02 | Methylgene, Inc. | Derivados de benzamida como inhibidores de histona desacetilasa |
| ZA200809148B (en) | 2006-04-18 | 2010-01-27 | Nippon Chemiphar Co | Activating agent for peroxisome proliferator activated receptor delta |
| US8653115B2 (en) | 2006-06-13 | 2014-02-18 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Heterocyclic non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents |
| KR101410318B1 (ko) | 2006-07-27 | 2014-06-27 | (주)아모레퍼시픽 | 바닐로이드 수용체 길항제로서의 신규 화합물, 그의 이성질체, 또는 약제학적으로 허용가능한 그의 염, 및 이를함유하는 약제학적 조성물 |
| TWI386405B (zh) | 2006-09-05 | 2013-02-21 | 咪唑衍生物 | |
| EP1939180A1 (en) | 2006-12-20 | 2008-07-02 | sanofi-aventis | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase |
| EP1942104A1 (en) | 2006-12-20 | 2008-07-09 | sanofi-aventis | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals |
| JP2010519337A (ja) | 2007-02-26 | 2010-06-03 | コーサン バイオサイエンシーズ， インコーポレイテッド | カルバメート化合物 |
| EP2003118A1 (de) | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Zimtsäurederivate als Modulatoren des EP2-Rezeptors |
| TW201011003A (en) | 2008-08-08 | 2010-03-16 | Synta Pharmaceuticals Corp | Triazole compounds that modulate HSP90 activity |
| US20110009374A1 (en) | 2009-07-09 | 2011-01-13 | Keller Brian C | Method of wound healing and scar modulation |
| US8518968B2 (en) | 2009-12-04 | 2013-08-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hydrazone and diacyl hydrazine compounds and methods of use |
| CN103002742B (zh) | 2010-03-05 | 2016-07-13 | 卡尔约药物治疗公司 | 核转运调节剂及其应用 |
| CA2824808A1 (en) * | 2011-01-17 | 2012-07-26 | Karyopharm Therapeutics, Inc. | Olefin containing nuclear transport modulators and uses thereof |
| JP6006794B2 (ja) | 2011-07-29 | 2016-10-12 | カリオファーム セラピューティクス，インコーポレイテッド | 核内輸送調節因子およびその使用 |
| KR20200088518A (ko) | 2011-07-29 | 2020-07-22 | 카리오팜 쎄라퓨틱스, 인코포레이티드 | 하이드라지드 함유 핵 수송 조절인자 및 이의 용도 |
| WO2013020024A2 (en) | 2011-08-03 | 2013-02-07 | Karyopharm Therapeutics, Inc. | Maleimide compounds and methods of treatment |
| HUE040427T2 (hu) | 2012-05-09 | 2019-03-28 | Biogen Ma Inc | Nukleáris transzportmodulátorok és felhasználásuk |
| WO2014152263A1 (en) | 2013-03-15 | 2014-09-25 | Karyopharm Therapeutics Inc. | Exo olefin-containing nuclear transport modulators and uses thereof |
| EP2968278B8 (en) | 2013-03-15 | 2019-05-22 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using crm1 inhibitors |
| WO2014205393A1 (en) | 2013-06-21 | 2014-12-24 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| MX365939B (es) | 2013-06-21 | 2019-06-19 | Karyopharm Therapeutics Inc | Moduladores del transporte nuclear y usos de los mismos. |
| WO2015073908A1 (en) | 2013-11-15 | 2015-05-21 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method for selecting cancer treatment regimen |
| JP6631616B2 (ja) | 2014-07-26 | 2020-01-15 | ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド | ＣＤＫ阻害剤としての２−アミノ−ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン誘導体及びその使用 |
| SG11201700789SA (en) | 2014-08-15 | 2017-02-27 | Karyopharm Therapeutics Inc | Polymorphs of selinexor |
| US10526295B2 (en) | 2015-12-31 | 2020-01-07 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| US10709706B2 (en) | 2015-12-31 | 2020-07-14 | Karopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| WO2017118940A1 (en) | 2016-01-08 | 2017-07-13 | Dr. Reddy's Laboratories Limited | Solid forms of selinexor and process for their preparation |
| US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
| US10993943B2 (en) | 2017-01-05 | 2021-05-04 | Watson Laboratories Inc. | Crystalline forms of selinexor and process for their preparation |
| EP3808742A1 (en) | 2019-10-16 | 2021-04-21 | Sandoz AG | Polymorph of selinexor |
| GB2591846B (en) | 2019-12-06 | 2024-08-14 | Bae Systems Plc | Light source |
| WO2022087218A1 (en) | 2020-10-21 | 2022-04-28 | Karyopharm Therapeutics Inc. | Crystalline form of selinexor |
-
2014
- 2014-06-20 MX MX2015016983A patent/MX365939B/es active IP Right Grant
- 2014-06-20 SI SI201431142T patent/SI3010892T1/sl unknown
- 2014-06-20 CN CN201480035555.8A patent/CN105339358B/zh active Active
- 2014-06-20 PT PT14738998T patent/PT3010892T/pt unknown
- 2014-06-20 WO PCT/US2014/043479 patent/WO2014205389A1/en not_active Ceased
- 2014-06-20 CA CA2915365A patent/CA2915365C/en active Active
- 2014-06-20 DK DK18202641.9T patent/DK3492455T3/da active
- 2014-06-20 UA UAA201600474A patent/UA119238C2/uk unknown
- 2014-06-20 PL PL14738998T patent/PL3010892T3/pl unknown
- 2014-06-20 KR KR1020217035649A patent/KR102545732B1/ko active Active
- 2014-06-20 CN CN201910389947.9A patent/CN110386919B/zh active Active
- 2014-06-20 RS RS20190400A patent/RS58581B1/sr unknown
- 2014-06-20 ME MEP-2019-88A patent/ME03421B/me unknown
- 2014-06-20 DK DK14738998.5T patent/DK3010892T3/en active
- 2014-06-20 CN CN201910393112.0A patent/CN110183422B/zh active Active
- 2014-06-20 ES ES18202641T patent/ES2952774T3/es active Active
- 2014-06-20 SG SG11201510036TA patent/SG11201510036TA/en unknown
- 2014-06-20 BR BR112015032071-6A patent/BR112015032071B1/pt active IP Right Grant
- 2014-06-20 EP EP14738998.5A patent/EP3010892B8/en active Active
- 2014-06-20 JP JP2016521862A patent/JP6730922B2/ja active Active
- 2014-06-20 KR KR1020167001020A patent/KR102322794B1/ko active Active
- 2014-06-20 HR HRP20190524TT patent/HRP20190524T1/hr unknown
- 2014-06-20 ES ES14738998T patent/ES2724275T3/es active Active
- 2014-06-20 SM SM20190184T patent/SMT201900184T1/it unknown
- 2014-06-20 EP EP18202641.9A patent/EP3492455B1/en active Active
- 2014-06-20 US US14/900,469 patent/US9738624B2/en active Active
- 2014-06-20 EA EA201690044A patent/EA029743B1/ru unknown
- 2014-06-20 HU HUE14738998A patent/HUE042800T2/hu unknown
- 2014-06-20 TR TR2019/04455T patent/TR201904455T4/tr unknown
- 2014-06-20 LT LTEP14738998.5T patent/LT3010892T/lt unknown
- 2014-06-20 AU AU2014284168A patent/AU2014284168B2/en active Active
-
2015
- 2015-12-10 ZA ZA2015/09015A patent/ZA201509015B/en unknown
- 2015-12-14 IL IL243099A patent/IL243099B/en active IP Right Grant
-
2017
- 2017-07-17 US US15/651,856 patent/US10407405B2/en active Active
-
2018
- 2018-09-05 IL IL261612A patent/IL261612A/en unknown
-
2019
- 2019-01-10 AU AU2019200147A patent/AU2019200147A1/en not_active Abandoned
- 2019-03-26 CY CY20191100349T patent/CY1122730T1/el unknown
- 2019-07-23 US US16/519,955 patent/US11124493B2/en active Active
-
2020
- 2020-07-03 JP JP2020115772A patent/JP7061161B2/ja active Active
- 2020-11-23 AU AU2020277088A patent/AU2020277088B2/en active Active
-
2021
- 2021-08-23 US US17/409,150 patent/US11945794B2/en active Active
-
2022
- 2022-12-06 AU AU2022283662A patent/AU2022283662A1/en not_active Abandoned
-
2024
- 2024-02-23 US US18/586,019 patent/US20250059158A1/en active Pending
- 2024-07-12 AU AU2024204818A patent/AU2024204818A1/en active Pending